DepYmed Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$250K
- Investors
-
7
DepYmed General Information
Description
Developer of potent inhibitors of the enzyme designed to offer therapeutics for cancer and rare diseases. The company develops novel small-molecule phosphatase inhibitors and copper-chelating compounds targeting protein tyrosine phosphatases, with applications across cancer, Wilson's Disease, Rett Syndrome, and other metabolic and rare disease indications, enabling pharmaceutical and biotechnology stakeholders to advance therapeutic candidates into clinical development.
Contact Information
Website
www.depymed.comCorporate Office
- 3 Bioscience Park Drive
- Farmingdale, NY 11735
- United States
Corporate Office
- 3 Bioscience Park Drive
- Farmingdale, NY 11735
- United States
DepYmed Timeline
DepYmed Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 10-Feb-2025 | $250K | Completed | Pre-Clinical Trials | ||
| 7. Later Stage VC | 16-Aug-2024 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC | 02-May-2023 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series A) | 07-Apr-2021 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A3) | 28-Oct-2016 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A1) | 30-Nov-2015 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 25-Mar-2015 | $100K | $100K | Completed | Startup | |
| 1. Joint Venture | 01-Jan-2014 | Completed | Startup |
DepYmed Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-1 | 532,310 | $0.000100 | 6% | $1.06 | $1.06 | 1x | $1.06 | 3.3% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
DepYmed Patents
DepYmed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019308311-A1 | (pyridinylmethyl)butanediamine derivatives that chelate copper | Active | 20-Jul-2018 | ||
| AU-2019308311-B2 | (pyridinylmethyl)butanediamine derivatives that chelate copper | Active | 20-Jul-2018 | ||
| CA-3110049-A1 | (pyridinylmethyl)butanediamine derivatives that chelate copper | Pending | 20-Jul-2018 | ||
| EP-3823977-A1 | (pyridinylmethyl)butanediamine derivatives that chelate copper | Active | 20-Jul-2018 | ||
| EP-3823977-A4 | (pyridinylmethyl)butanediamine derivatives that chelate copper | Active | 20-Jul-2018 | A61P1/16 |
DepYmed Signals
DepYmed Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Topspin Consumer Partners | PE/Buyout | Minority | ||
| Jove Equity Partners | Venture Capital | Minority | ||
| Accelerate Long Island | Accelerator/Incubator | Minority | ||
| Long Island Emerging Technologies Fund | Venture Capital | Minority | ||
| Cold Spring Harbor Laboratory | Corporation | Minority |
DepYmed FAQs
-
When was DepYmed founded?
DepYmed was founded in 2014.
-
Where is DepYmed headquartered?
DepYmed is headquartered in Farmingdale, NY.
-
What is the size of DepYmed?
DepYmed has 2 total employees.
-
What industry is DepYmed in?
DepYmed’s primary industry is Drug Discovery.
-
Is DepYmed a private or public company?
DepYmed is a Private company.
-
What is DepYmed’s current revenue?
The current revenue for DepYmed is .
-
How much funding has DepYmed raised over time?
DepYmed has raised $14.3M.
-
Who are DepYmed’s investors?
Topspin Consumer Partners, Jove Equity Partners, Accelerate Long Island, Long Island Emerging Technologies Fund, and Cold Spring Harbor Laboratory are 5 of 7 investors who have invested in DepYmed.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process